Second edition · September 2026 · regulatory cut-off 7 September 2026
One text, three legal regimes, five applicability dates. And one shared deadline: 15 January 2027.
On 15 January 2027 two documents become applicable in the European Union at the same moment: the consolidated version of ICH E6(R3) (EMA/CHMP/ICH/162879/2026) and Annex 2 (EMA/CHMP/ICH/495903/2024). This guide is the readiness path to that date: 27 chapters in six parts that read E6(R3) clause by clause, state in which jurisdiction each sentence is law and in which it is only a recommendation, and close on the sixteen-week plan. 232 pages in the Italian edition, 233 in the English, and 17 editable tools, for €129.
232 pages (ITA) · 233 (ENG) · A4 PDF27 chapters in six parts + 5 appendices17 editable tools per languageWritten on the consolidated text of 15/07/2026161 sources in the register152 decisions trackedFive dates, six jurisdictions
Two editions, not two languages in one file. The guide and the toolkit exist in two editions only, Italian and English, identical in structure: choose the ITA - Italiano or the ENG - English variant. Purchase gives access to the edition you choose.
The guide
27 chapters in six parts that read E6(R3) in the order of the text: the eleven Principles, Annex 1 section by section up to Data Governance, Annex 2 (which applies in the EU from 15/01/2027), the three legal regimes, the systems the inspector looks at. Every chapter follows the same sequence — what the text says → with which verb → in which jurisdiction it holds → what the sponsor decides → in which document it is recorded → how it is demonstrated at inspection — and closes with the decisions it produces.
The toolkit
17 editable tools per language: 10 Excel workbooks with live formulas, data validation and instruction sheets, and 7 Word documents with model text, revision history and approval tables. 34 files in all. The first is the gap assessment against the Principles and Annex 1; the second is the countdown to Annex 2, and the two are read together.
Lifetime updates
The framework moves, and the dates are already written: the consolidated version and Annex 2 apply in the EU from 15 January 2027; 31 December 2026 is the last day ICH keeps Annex 2 as a standalone document; E2D(R1) has been in force in the EU since 18 March 2026. When the texts change you receive the revised guide and toolkit at no extra cost.
€129, and the date is not moving
This edition is written on the consolidated version of 15 July 2026 (EMA/CHMP/ICH/162879/2026), with both Error Corrections — 24 October 2025 and 16 June 2026 — already applied. Anyone working from the PDF downloaded in January 2025 is citing a text that has been corrected twice since: in the EU the consolidated version and Annex 2 apply from 15 January 2027, and from that day it is that text you are read against.
The price is €129.00. Second edition, September 2026, with a regulatory verification cut-off of 7 September 2026: 232 pages in the Italian edition, 233 in the English, 27 chapters, 5 appendices and 34 editable files. Anyone who bought the first edition receives this one at no extra cost.
The 17 tools in the toolkit
Ten Excel and seven Word, in Italian and in English: 34 files. No operational value is pre-loaded. Monitoring frequencies, sample sizes, risk scoring scales, deviation classification thresholds: these are "to be defined" placeholders, because E6(R3) fixes none of them, and every example row is declared fictitious on the row where it appears. Every row that carries an expectation states the clause, the verb of the text and the jurisdiction in which that expectation has force.
EXCEL01 · E6(R3) Gap Assessment — Principles and Annex 1, clause by clause
The centre of the toolkit. Pre-loaded rows for the Principles and for the sections of Annex 1, with the verb of the text, the jurisdiction in which the expectation has force, the status, the evidence and the gap. The status field has four values, not three: compliant with evidence, partial, gap, sponsor decision to be justified.
EXCEL02 · Annex 2 Readiness Assessment — countdown to 15/01/2027
The assessment on decentralised elements, pragmatic elements and real-world data, with the target date of 15 January 2027 and the link to the sixteen-week plan. Every row states that in the EU Annex 2 applies from 15/01/2027 and is not a requirement before then.
EXCEL03 · Critical to Quality Factors Register
The CtQ factors one by one: what they protect, how they were selected, which control holds them, which evidence demonstrates them and who approved the choice. It is the register that answers the question "how did you establish that this one is critical".
EXCEL04 · Risk Assessment and Risk Control Register (cycle §3.10.1.1–3.10.1.6)
The Annex 1 §3.10.1 cycle step by step — identification, evaluation, control, communication, review, reporting — in a single register. No scoring scale is pre-loaded: the scale is a sponsor decision and the sheet asks you to declare it.
EXCEL05 · Monitoring Plan Builder — derived from risk, not standalone
In E6(R3) monitoring is no longer a section of its own: it is §3.11.4, quality control downstream of risk management. The builder starts from the CtQ factors and the risks in tool 04 and derives activities, the on-site / remote / centralised mix and frequencies, keeping the derivation traceable.
EXCEL06 · TMF Index and Completeness Tracker — with retention regime selector
The TMF index in the vocabulary of essential records, with completeness and timeliness by section. The retention regime selector applies the right regime: 25 years in the EU (art. 58 Reg. 536/2014), 25 or 5 years in the United Kingdom depending on the application date, with the post-authorisation extension.
EXCEL07 · Computerised Systems Inventory and Validation Status
Systems, suppliers, data criticality, validation status, audit trail, access management and retention. It is the inventory that connects Annex 1 section 4 to the EMA guideline on computerised systems and to the MHRA and FDA documents on electronic data.
EXCEL08 · Service Provider and CRO Oversight Matrix — delegation and accountability
Who does what, what is delegated, what cannot be delegated and how the sponsor verifies it. The matrix keeps delegation of the activity and accountability that stays with the sponsor apart, which is exactly where the findings concentrate.
EXCEL09 · Multi-jurisdiction Applicability Matrix — EU / UK / US / CA / JP / CH
Six jurisdictions in columns, each with its applicability date and its legal force: EU 23/07/2025, Switzerland 15/08/2025, United States 09/09/2025, Canada 01/04/2026, United Kingdom 28/04/2026, Japan not yet implemented. This is the tool you use to decide what holds at which site of a multi-regional study.
EXCEL10 · Inspection Findings and CAPA Tracker
Finding, category, area, root cause, CAPA, owner, due date, effectiveness check. The categories follow the areas where published findings actually concentrate — essential documents, source data, monitoring, data management — so that the register also tells you where the system leaks.
WORD11 · Quality Management SOP — quality by design and RBQM
The SOP that lines up quality by design, CtQ factors, risk management and quality control along the architecture of §3.10 and §3.11. Model text, with the points where the organisation has to insert its own decision clearly marked.
WORD12 · Monitoring Plan — model linked to the risk assessment
The plan that comes out of tool 05: scope, activities, frequencies, escalation, deviation handling and reporting, with an explicit cross-reference to the risk assessment that generated it. A Monitoring Plan without that cross-reference is outside the architecture by construction.
WORD13 · Protocol Deviation Management SOP
Detection, classification, assessment of the impact on the CtQ factors, action, reporting and closure. The classification does not arrive pre-loaded with numeric thresholds: thresholds are a sponsor decision, and the SOP asks you to write yours.
WORD14 · Sponsor Oversight Plan and delegation schedule
The sponsor oversight plan and the delegation schedule towards CROs and service providers, aligned with the matrix in tool 08. It includes the control points, their frequency and the evidence each one leaves behind.
WORD15 · Annex 2 / Decentralised Elements Impact Assessment
The impact assessment on decentralised elements, pragmatic elements and real-world data, including in the format MHRA expects for trials that started before 28 April 2026. Every reference to Annex 2 states that in the EU it applies from 15/01/2027.
WORD16 · GCP Training and Competence Pack
The training pack: what changed with R3, what changes role by role, the competence check and the training record. It is the document you show when the inspector asks for proof that the team knows the applicable text.
WORD17 · Inspection Simulation Kit — twenty questions with expected evidence and red flags
Twenty inspection questions, each anchored to a clause or an article, with the expected evidence and the corresponding red flag. Use it as an internal simulation before the real inspection, and as a self-assessment grid afterwards.
You can use it from tomorrow morning
| The situation | What you use |
|---|
| I need to know whether we are ready for 15 January 2027 | Chapters 13 → 16 + Tools 02 and 15: what becomes applicable on that day and for whom, the sixteen-week plan expressed in relative weeks, and the impact assessment on decentralised elements |
Our SOPs cite EMA/CHMP/ICH/135/1995 and nothing more | Chapters 1 and 3: which code, which version and which date actually identify the text, and why the code on its own identifies nothing after two Error Corrections and a consolidated version |
| We have an open trial with sites in the EU, the UK and the United States | The whole of Part IV (chs. 17-21) + Tool 09: the same text in three different legal states, and the comparative table that says what is law where |
| Our Monitoring Plan is a standalone document | Chapter 9 + Tools 04, 05 and 12: in E6(R3) monitoring is §3.11.4, downstream of risk management. The builder derives the plan from the risks, and the derivation stays traceable |
| MHRA is asking us for the impact assessment for pre-28 April 2026 trials | Chapters 18 and 26 + Tool 15: MHRA states that a line-by-line assessment of Annex 1 is not required to be documented — the chapter explains what is needed instead, and in what form |
| I do not know which retention regime applies to our TMF | Chapter 23 + Tool 06: 25 years in the EU under art. 58; in the United Kingdom 25 years for new trials and 5 for legacy ones, with participant medical files always at 25 and the post-authorisation extension |
| Our procedures still cite the two EMA reflection papers | Chapter 22: the reflection papers on RBQM (EMA/269011/2013) and on electronic source data (EMA/INS/GCP/454280/2010) are superseded, and thousands of SOPs still cite them. It is a documentary finding you can close at zero cost |
| We have a GCP inspection in two weeks | Chapters 25 and 27 + Tools 17 and 10: the published inspection figures with their denominators, twenty questions with the expected evidence and the red flag, and the findings register |
Why the version of the text you cite is the first thing an inspector checks
Three successive versions of E6(R3) exist, and they are not interchangeable. The original Step 4 of 6 January 2025; the Error Correction of 24 October 2025, which the ICH Document History describes as typographical corrections to the references in Sections 1.2.5 and 3.16.4; and the consolidated version of 16 June 2026, published by EMA on 15 July 2026, which absorbs Annex 2 and carries a second round of corrections to Annex 1 §§ 3.6.6, 3.11.4.5.2(b), 3.16.1(u), Appendix A §A1.1 and to the glossary entry IRB/IEC. This edition is written on that consolidated version, which applies in the EU from 15 January 2027.
One text, three legal regimes — and the book never writes "E6 requires X" without saying where. In the European Union the obligation is Reg. (EU) 536/2014, and art. 47 requires that appropriate account be taken of the ICH guidelines: a duty of consideration, not an obligation of clause-by-clause conformity. In the United Kingdom the eleven Principles have been law since 28 April 2026 through regulation 28(1A), introduced by SI 2025/538, with an ambulatory reference to the ICH text — while the Annexes only have to be had regard to. In the United States E6(R3) is a non-binding FDA guidance: the applicable requirement remains 21 CFR.
Five applicability dates, and one jurisdiction that has not yet implemented. European Union 23/07/2025, Switzerland 15/08/2025, United States 09/09/2025, Canada 01/04/2026, United Kingdom 28/04/2026; Japan has not yet implemented E6(R3). The table with a source on every row is Chapter 2, and it becomes operational in tool 09.
The inspection figures are the published ones, with their denominators. From the EMA 2024 report: out of 335 major and critical findings, 9 of the 11 critical ones — 81.8 % — are attributed to the sponsor and none to the investigator; the most affected subcategories are Essential Documents (41), Source Documentation (38), Monitoring (35) and Data Management (27); only 22.4 % of the 67 inspections took place in the EU/EEA. The chapter also states that from the 2024 report EMA no longer publishes minor findings, so the totals are not comparable with earlier years: the time series is not drawn.
No date, no code and no figure without a source. The book works with eleven labels that declare, at every citation, whether a document is current, not yet applicable with its date, draft or superseded, and with what force it speaks: legal requirement, authority expectation, good practice or editorial work of our own. Regulatory cut-off 7 September 2026, with a register of 161 sources — title, code, version, date, status, URL and access date — and 152 decisions tracked, each with who takes it, where it is recorded and with which tool.
Inside the guide
Part I — What has changed, and why now (chs. 1-4). How to use the guide and the five reading routes; the calendar of the dates that decide, from 2025 to 2028, with the distinction between ICH Step 4, CHMP adoption and the applicability date; what E6(R3) is, the eleven Principles and the consolidated version; and the inventory of the ICH E series from E1 to E23, including E21, E22 and E23.
Part II — E6(R3) clause by clause (chs. 5-12). Annex 1 in the order of the text: the Principles and their legal weight; architecture, scope and the IRB/IEC; investigator, site and informed consent; risk management and critical to quality factors with the §3.10.1.1–3.10.1.6 cycle; quality control and monitoring as §3.11.4; safety, investigational product and records; Data Governance with ALCOA++; Appendices A, B, C and the glossary.
Part III — Annex 2: readiness for 15 January 2027 (chs. 13-16). What Annex 2 is and what it is not, with its status in each jurisdiction; decentralised elements compared with the EU Recommendation paper and with the FDA guidances; pragmatic elements and real-world data; and the sixteen-week readiness plan, expressed in relative weeks so that the countdown starts on the day you read it.
Part IV — One text, three regimes (chs. 17-21). European Union: Reg. (EU) 536/2014, art. 47 and art. 58, CTIS and ACT EU. United Kingdom: SI 2025/538, regulation 28(1A), the dual regime for trials before and after 28 April 2026. United States: 21 CFR and the non-binding character of guidance. Canada, Switzerland, Japan and multi-regional trials. And the comparative table of what is law where.
Part V — The systems the inspector looks at (chs. 22-24). Computerised systems, audit trails and data integrity, with the EMA, MHRA and FDA documents and the two superseded EMA reflection papers that thousands of SOPs still cite; TMF and essential records, with retention periods by jurisdiction; safety reporting, where SUSARs go to EudraVigilance and the annual safety report goes to CTIS, in E2B(R3) format.
Part VI — Proving it at inspection (chs. 25-27). The real inspection figures, published only and with the denominator declared, including the gaps nobody fills; the method for a gap assessment against E6(R3), with the UK version MHRA expects; and inspection readiness in a "what an inspector may ask" format, with at least twenty questions anchored to a clause or an article.
Plus 5 appendices. The register of 161 sources with title, code, version, date, status, URL and access date; the regulatory status matrix, document by document and jurisdiction by jurisdiction; the 152 decisions the guide produces, each with who takes it, where it is recorded and with which tool; the 17 tool sheets; and the glossary of the entries that change from R2, starting with essential records in place of essential documents.
Read 22 pages before you buy
The free extract is made of 22 real pages, not a sales summary: the regulatory status panel with the eleven labels and the half page on 15 January 2027; the full table of contents with the real page numbers; the calendar of applicability dates; the opening of the Annex 2 chapter; and the complete list of the 17 tools with their source chapter and intended user.
Specifications
| Format | A4 PDF — 232 pages (ITA edition) · 233 pages (ENG edition) |
| Edition | Second edition · September 2026 · version 2.0. Supersedes the first edition. |
| Structure | 27 chapters in six parts + 5 appendices |
| Reference text | ICH E6(R3) consolidated version EMA/CHMP/ICH/162879/2026, published by EMA on 15/07/2026, applicable in the EU from 15/01/2027; Annex 2 EMA/CHMP/ICH/495903/2024, applicable in the EU from 15/01/2027. Both Error Corrections (24/10/2025 and 16/06/2026) are already applied. |
| Jurisdictions covered | European Union (23/07/2025), Switzerland (15/08/2025), United States (09/09/2025), Canada (01/04/2026), United Kingdom (28/04/2026); Japan not yet implemented |
| Toolkit | 17 editable tools per language: 10 Excel workbooks and 7 Word documents — 34 files in all |
| Languages | The guide and the toolkit exist in two editions only, Italian and English, identical in structure: choose the ITA - Italiano or the ENG - English variant. |
| Sources | A register of 161 sources cited, with title, code, version, date, status, URL and access date |
| Decisions | 152 decisions tracked: who takes it, where it is recorded, with which tool of the toolkit |
| Regulatory cut-off | 7 September 2026 |
| Free preview | 22 pages per language |
| Price | €129.00 |
| Delivery and licence | Immediate download after purchase. Individual use, internal to the purchasing company. Digital product: no physical shipment. |
Who it is for. Clinical Operations and Clinical Trial Managers, GCP QA and auditors, Sponsor Oversight, Regulatory Affairs, Data Management and Biometrics, Pharmacovigilance for the part that touches the trial, TMF Managers, CROs and service providers, investigator sites, consultants. It is written for people who already have the text of E6(R3) and have to apply it: it does not explain what a clinical trial is and it does not summarise GCP. It explains which clause governs a matter, with which verb, in which jurisdiction that sentence has force and what is shown at inspection.
Who it is not for. It is not the text of E6(R3), which has to be read, and read in the right version. It is not a biostatistics manual: E9 and E9(R1) enter as an object of the protocol and of data governance, not as a methodological treatment. It is not the guide to post-authorisation pharmacovigilance — the QPPV, the PSMF and the GVP modules stay with the dedicated guide, and the boundary is declared every time it is reached. And it is not legal advice: the legal readings are reconstructions anchored to precisely cited texts, not opinions.
Do you have to be ready for 15 January 2027, or defend a choice in front of an inspector?
Describe your study portfolio, the jurisdictions involved and the point where you are stuck. GuideGxP will assess the request and, where appropriate, may put you in touch with a specialist matched to your technical needs and your geographical area.
Describe your situation →
No obligation to buy. Every request is assessed before any referral to a specialist.
GuideGxP guides do not replace official regulations (ICH, EMA, European Commission, MHRA, FDA, Health Canada, Swissmedic, PMDA, PIC/S, WHO, ISO): they are operational support tools, and the user remains responsible for correctly applying the regulations in force in their own company context. The official texts of ICH E6(R3), of Annex 2 (applicable in the EU from 15/01/2027) and of the regulations cited are freely available and should be kept to hand while reading: this guide does not replace them. Content relating to texts that are not yet applicable — in particular the consolidated version EMA/CHMP/ICH/162879/2026 and Annex 2 EMA/CHMP/ICH/495903/2024, which apply in the European Union from 15 January 2027 — serves readiness and does not constitute a requirement before that date. ICH guidelines have no force of law in themselves: binding force comes from regional implementation, which this guide states jurisdiction by jurisdiction. Digital product: no physical shipment.
